Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C - PubMed (original) (raw)
Review
. 2003 Nov-Dec;13(6):361-71.
doi: 10.1002/rmv.397.
Affiliations
- PMID: 14625884
- DOI: 10.1002/rmv.397
Review
Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C
Thomas Hügle et al. Rev Med Virol. 2003 Nov-Dec.
Abstract
Current therapeutic options for hepatitis C are limited, especially for genotype 1. For genotypes 2 and 3, pegylated interferon in combination with ribavirin, can lead to a sustained virological response in up to 80% of patients. Unfortunately, adverse effects of IFN and ribavirin are a major problem and the list of contraindications for HCV therapy is long, including decompensated cirrhosis of the liver and psychiatric disorders. Therefore, alternative therapeutic approaches are needed. New delivery options for IFN and ribavirin are aimed at optimising efficiency and reducing adverse effects. Recent progress in the molecular virology of HCV has identified new targets for antiviral intervention. Inhibition of HCV gene expression and replication as well as immunotherapeutic concepts aimed at enhancing the cellular immune response against HCV are being explored. Solution of the crystal structures of HCV key enzymes led to the design of specific inhibitors including compounds active against the well characterised NS3 serine protease and RNA-dependent RNA polymerase which are currently in the early phase clinical investigation. New strategies for inhibiting HCV gene expression include the use of antisense oligodeoxynucleotides and ribozymes. Immunomodulation by agents such as inosine monophosphate dehydrogenase inhibitors, thymosin-alpha 1, histamine or amantadine are being studied in combination with IFN and/or ribavirin. Immunotherapeutic vaccination with recombinant HCV E1 protein improved host immunity against HCV and thus seems to be a promising new option.
Copyright 2003 John Wiley & Sons, Ltd.
Similar articles
- New therapies for the treatment of chronic hepatitis C.
Idéo G, Bellobuono A. Idéo G, et al. Curr Pharm Des. 2002;8(11):959-66. doi: 10.2174/1381612024607009. Curr Pharm Des. 2002. PMID: 11945142 Review. - Antiviral strategies in hepatitis C virus infection.
Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Sarrazin C, et al. J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. J Hepatol. 2012. PMID: 22300469 Review. - [Experimental therapy in HCV infection].
Inglot M, Gładysz A, Rymer W. Inglot M, et al. Przegl Epidemiol. 2005;59(2):525-33. Przegl Epidemiol. 2005. PMID: 16190563 Review. Polish. - Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Poo JL, Sánchez-Avila F, Kershenobich D, García-Samper X, Gongora J, Uribe M. Poo JL, et al. J Gastroenterol Hepatol. 2004 Dec;19 Suppl 6:S79-81. doi: 10.1111/j.1440-1746.2004.03634.x. J Gastroenterol Hepatol. 2004. PMID: 15546256 Clinical Trial. - Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E. Hofmann WP, et al. Antivir Ther. 2011;16(5):695-704. doi: 10.3851/IMP1821. Antivir Ther. 2011. PMID: 21817191
Cited by
- QSAR study of HCV NS5B polymerase inhibitors using the genetic algorithm-multiple linear regression (GA-MLR).
Rafiei H, Khanzadeh M, Mozaffari S, Bostanifar MH, Avval ZM, Aalizadeh R, Pourbasheer E. Rafiei H, et al. EXCLI J. 2016 Jan 18;15:38-53. doi: 10.17179/excli2015-731. eCollection 2016. EXCLI J. 2016. PMID: 27065774 Free PMC article. - Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.
Kim HJ, Sharon A, Bal C, Wang J, Allu M, Huang Z, Murray MG, Bassit L, Schinazi RF, Korba B, Chu CK. Kim HJ, et al. J Med Chem. 2009 Jan 8;52(1):206-13. doi: 10.1021/jm801418v. J Med Chem. 2009. PMID: 19072694 Free PMC article. - RNA interference against viruses: strike and counterstrike.
Haasnoot J, Westerhout EM, Berkhout B. Haasnoot J, et al. Nat Biotechnol. 2007 Dec;25(12):1435-43. doi: 10.1038/nbt1369. Nat Biotechnol. 2007. PMID: 18066040 Free PMC article. Review. - Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening.
Zhang Y, Weady P, Duggal R, Hao W. Zhang Y, et al. Antimicrob Agents Chemother. 2008 Feb;52(2):666-74. doi: 10.1128/AAC.01133-07. Epub 2007 Nov 26. Antimicrob Agents Chemother. 2008. PMID: 18039917 Free PMC article. - Modulation of host metabolism as a target of new antivirals.
Ikeda M, Kato N. Ikeda M, et al. Adv Drug Deliv Rev. 2007 Oct 10;59(12):1277-89. doi: 10.1016/j.addr.2007.03.021. Epub 2007 Aug 11. Adv Drug Deliv Rev. 2007. PMID: 17897752 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources